WAYNE, Pa., May 24, 2016 /PRNewswire/ -- Ryan &
Maniskas, LLP is investigating potential claims against the board
of directors of XenoPort, Inc. ("XenoPort" or the "Company")
(NASDAQ: XNPT) concerning possible breaches of fiduciary duty and
other violations of law related to the Company's efforts to sell
the Company to Arbor Pharmaceuticals, LLC in a transaction valued
at approximately $467 million.
If you own shares of XenoPort and would like to learn more about
this class action or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/xnpt. You may also email Mr. Maniskas at
rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of XenoPort will
receive $7.03 in cash for each share
of XenoPort common stock.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by the Board of Directors of
XenoPort or not acting in the Company's shareholders' best
interests in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas,
LLP
Richard A. Maniskas,
Esquire
995 Old Eagle School Rd., Suite
311
Wayne, PA
19087
877-316-3218
www.rmclasslaw.com/cases/xnpt
rmaniskas@rmclasslaw.com
Logo -
http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-investigation-of-xenoport-inc-300273963.html
SOURCE Ryan & Maniskas, LLP